What Sponsors Should Look for When Selecting a Clinical Research Site in Mexico

Mexico has become a more active part of global and regional trial planning, particularly for sponsors looking to diversify patient populations or shorten timelines through sites near the U.S. border. But evaluating a Mexico-based site requires more than the standard feasibility checklist. Regulatory pathway, documentation language, and cross-border logistics all add variables that don't come up when evaluating a domestic U.S. site.

Below is a practical framework for what to look for — and where Renova Clinical Trials fits against it.

1. Regulatory Pathway and Site Authorization

Any site conducting a clinical trial in Mexico operates under COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), the country's federal health regulator. Before a sponsor can enroll a single participant, the trial protocol needs a favorable opinion from a registered research ethics committee, followed by COFEPRIS authorization submitted through DIGIPRiS, its digital regulatory platform. The site itself must also hold a valid notice of operation and demonstrate it has the resources to conduct the research and manage a medical emergency if one occurs. All submission documentation is required in Spanish.

Sponsors should ask directly: Is the site currently authorized to operate, and does it have prior experience navigating the ethics-committee and COFEPRIS submission process? A site that has never been through this pathway adds startup risk that's easy to underestimate.

One development worth knowing about: recent COFEPRIS reforms have introduced reliance criteria that allow expedited review for Phase III protocols already approved by the FDA, EMA, or Health Canada, which has shortened timelines for some multinational sponsors. This is a meaningful shift, but timelines still vary by protocol and product type, so sponsors should confirm current expectations directly with the site and their regulatory team rather than assuming a fixed timeline.

2. Infrastructure That Matches the Protocol

Feasibility research consistently shows that patient population access, site resources, and data collection procedures are among the top factors sponsors and CROs weigh when comparing sites. For procedure-oriented or high-touch protocols specifically, infrastructure questions get more specific:

• Is there dedicated procedure or exam space, or will patient flow compete with unrelated clinical operations?

• Is there on-site specimen processing, or does every sample require offsite transport?

• Is investigational product storage temperature-controlled and separately documented?

• Is there a defined space for sponsor and CRO monitoring visits?

A site that can answer these clearly, with physical infrastructure to match, reduces a category of startup delay that's common when sites overstate their readiness during feasibility surveys.

3. Investigator Experience and Engagement

Site personnel experience and the investigator's own trial background are consistently rated among the highest-weighted criteria in site-selection research, often above cost considerations. This isn't just about a CV — it's about whether the Principal Investigator is positioned to be genuinely involved in day-to-day study conduct, or whether oversight is largely delegated and administrative.

Sponsors evaluating a site should ask about the PI's clinical background independent of research work, prior trial roles, relevant certifications (GCP, IATA for trial materials handling, emergency response credentials), and how the PI is actually involved during a typical study week — not just at startup and closeout.

4. Bilingual Operations and Cross-Border Patient Access

Sites in the San Diego–Tijuana corridor have a structural advantage that's specific to this geography: direct access to a bilingual, cross-border patient population, combined with proximity to U.S.-based sponsors and CRO teams for site visits. For sponsors running studies with English- and Spanish-speaking participant pools, or those who want the option of in-person oversight without a long-haul trip, this corridor reduces friction that shows up elsewhere in the study.

This should be evaluated carefully rather than assumed. A site's physical location in the corridor doesn't automatically mean day-to-day operations run bilingually — sponsors should confirm whether informed consent, source documentation, and staff communication are genuinely conducted in both languages as needed, not just available on request.

5. Communication and Operational Discipline

Feasibility researchers and CRO site-selection teams increasingly flag responsiveness and communication as differentiators separate from raw capability — a site can have excellent infrastructure and still create friction if query resolution is slow or monitoring visits are hard to schedule. Sponsors should ask how a site handles routine communication: standard response time for monitor questions, how deviations are reported, and who the primary point of contact is throughout the study, not just at initiation.

Where Renova Clinical Trials Fits

Renova Clinical Trials is a physician-led clinical research site in Tijuana, Baja California, within the San Diego–Tijuana clinical research corridor. The site operates within a multi-specialty ambulatory surgical center with seven exam rooms, one operating room, on-site specimen processing, temperature-controlled investigational product storage, dedicated IP preparation and dispensing, a monitoring room built for sponsor and CRO visits, and a recovery bay — infrastructure built around procedure-oriented and high-touch protocols specifically, rather than adapted from a general clinic.

Dr. Rene Veytia, Principal Investigator and CEO, brings more than 15 years of medical leadership and more than 8 years of specialized experience in pharmaceutical and biotech clinical development, including GI and rare disease trial work, GCP (ICH E6) and IATA certification, and Medical Affairs experience across Mexico and Latin America. Operations run bilingually in English and Spanish.

Sponsors evaluating the site directly, rather than relying on summary claims, remain the standard — and Renova's team is available to walk through current regulatory status, facility specifics, and PI availability directly.

A Note on What Mexico-Based Research Is Not

It's worth addressing directly: sites in Mexico are not a shortcut around regulatory rigor or participant protection standards. COFEPRIS oversight, ethics committee review, and GCP compliance apply in full, and reputable sites should be evaluated on the same safety, data quality, and ethical standards as any U.S. or European site — with the added logistics of a cross-border regulatory pathway factored in, not a reduced bar.

Conclusion

Selecting a Mexico-based site involves the same core questions sponsors ask anywhere — patient access, infrastructure, investigator engagement, communication — plus a regulatory pathway and documentation process specific to COFEPRIS. Sites that can speak clearly to both categories, with verifiable specifics rather than general claims, are the ones worth prioritizing in feasibility review.

Author: Renova Clinical Trials Clinical Team